Cellectis S.A. - American Depositary Shares (CLLS)
CLLS moved a median of -0.01% 30 minutes after news, and -0.91% by the close. How CLLS actually reacts to news — the realized, point-in-time move the market made, measured across 285 labeled events over the last three years with zero look-ahead.
CLLS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 29% | 257 |
| 30-min | -0.01% | 37% | 279 |
| 60-min | -0.49% | 36% | 280 |
| to close | -0.91% | 40% | 277 |
| Middle 50% of CLLS reactions | -1.95% to +0.57% |
|---|---|
| Median reaction (30-min) | -0.01% |
| Measured reactions | 285 |
Half of all Cellectis S.A. - American Depositary Shares news events land between -1.95% and +0.57% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CLLS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 11 | -0.35% | 27% | -2.42% |
| Coverage initiations | 51 | -0.61% | 35% | -1.18% |
| Rating reiterations | 14 | -1.51% | 21% | -2.42% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how CLLS ranks against every other measured name →
That’s how CLLS usually reacts — get an email when it moves on news →Email me when CLLS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CLLS's baseline. Nothing else.
Recent CLLS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Cellectis S.A. (CLLS) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | — | +0.00% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cellectis S.A. (CLLS) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | — | -0.66% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Cellectis S.A. (CLLS) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | — | +2.44% | |
| Cellectis S.A. (CLLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.62% | -0.74% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Cellectis S.A. (CLLS) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | — | -2.57% | |
| CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law | Press release | Business Wire | -1.31% | -1.31% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cellectis S.A. (CLLS) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | -0.33% | +0.00% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Cellectis S.A. (CLLS) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.00% | -0.68% | |
| Cellectis Reports Financial Results for the Second Quarter 2026 | Press release | GlobeNewswire | +1.11% | +5.00% | |
| Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026 | Press release | GlobeNewswire | -0.70% | -1.05% | |
| Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL | Press release | GlobeNewswire | -0.61% | -2.15% | |
| Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform | Press release | GlobeNewswire | +0.00% | -1.66% | |
| Form 20-F Cellectis S.A. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +0.00% | -0.30% | |
| Form 6-K Cellectis S.A. For: Mar 19 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.30% | |
| Form 6-K Cellectis S.A. For: Mar 12 | SEC filing · Form 6-K | SEC EDGAR | — | -3.12% | |
| Form 6-K Cellectis S.A. For: Jan 08 | SEC filing · Form 6-K | SEC EDGAR | -1.77% | -2.22% | |
| Form 6-K Cellectis S.A. For: Dec 15 | SEC filing · Form 6-K | SEC EDGAR | -3.29% | -4.70% | |
| Form 6-K Cellectis S.A. For: Dec 08 | SEC filing · Form 6-K | SEC EDGAR | -0.84% | -2.53% | |
| Form 6-K Cellectis S.A. For: Dec 05 | SEC filing · Form 6-K | SEC EDGAR | -0.84% | -2.53% | |
| Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells | Press release | GlobeNewswire | +0.00% | -3.30% | |
| Form 6-K Cellectis S.A. For: Nov 19 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -3.30% | |
| Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.00% | -1.11% | |
| Form 6-K Cellectis S.A. For: Nov 07 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -1.11% | |
| Cellectis to Present a Development Update for eti-cel at ASH 2025 | Press release | GlobeNewswire | +0.61% | -0.91% | |
| Form 6-K Cellectis S.A. For: Nov 03 | SEC filing · Form 6-K | SEC EDGAR | +0.61% | -0.91% | |
| Form 6-K Cellectis S.A. For: Oct 29 | SEC filing · Form 6-K | SEC EDGAR | +0.61% | -0.91% | |
| Form 6-K Cellectis S.A. For: Oct 16 | SEC filing · Form 6-K | SEC EDGAR | +0.23% | -9.54% | |
| Form 6-K Cellectis S.A. For: Oct 16 | SEC filing · Form 6-K | SEC EDGAR | +2.85% | -13.08% | |
| Form 6-K/A Cellectis S.A. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.24% | |
| Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress | Press release | GlobeNewswire | -0.65% | +2.69% | |
| Form 6-K Cellectis S.A. For: Oct 07 | SEC filing · Form 6-K | SEC EDGAR | -0.65% | +2.69% | |
| Form S-8 Cellectis S.A. | SEC filing · Form S-8 | SEC EDGAR | +2.17% | -1.97% | |
| Form 6-K Cellectis S.A. For: Aug 04 | SEC filing · Form 6-K | SEC EDGAR | -10.71% | -17.86% | |
| Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025 | Press release | GlobeNewswire | -4.87% | — | |
| Form 6-K Cellectis S.A. For: Jul 28 | SEC filing · Form 6-K | SEC EDGAR | -4.87% | — | |
| Form EFFECT Cellectis S.A. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +32.72% | |
| Form F-3 Cellectis S.A. | SEC filing · Form F-3 | SEC EDGAR | -1.85% | -2.47% | |
| Form 6-K Cellectis S.A. For: Jun 26 | SEC filing · Form 6-K | SEC EDGAR | +1.36% | -1.36% | |
| Form 6-K Cellectis S.A. For: May 21 | SEC filing · Form 6-K | SEC EDGAR | -0.66% | +0.02% | |
| Form 6-K Cellectis S.A. For: May 12 | SEC filing · Form 6-K | SEC EDGAR | +1.41% | -0.70% | |
| Form 6-K Cellectis S.A. For: May 06 | SEC filing · Form 6-K | SEC EDGAR | — | -4.69% | |
| Form 6-K Cellectis S.A. For: Apr 28 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +3.25% | |
| Form 6-K Cellectis S.A. For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | -0.80% | +5.60% | |
| Form 20-F Cellectis S.A. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -4.21% | -11.43% | |
| Form 20-F/A Cellectis S.A. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -0.85% | +0.41% | |
| Form 6-K Cellectis S.A. For: Mar 07 | SEC filing · Form 6-K | SEC EDGAR | +2.38% | -3.17% | |
| Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 | Press release | GlobeNewswire | -0.01% | -1.45% | |
| Form 6-K Cellectis S.A. For: Feb 24 | SEC filing · Form 6-K | SEC EDGAR | -0.01% | -1.45% | |
| Form EFFECT Cellectis S.A. | SEC filing · Form EFFECT | SEC EDGAR | -1.60% | +5.03% | |
| Form F-3 Cellectis S.A. | SEC filing · Form F-3 | SEC EDGAR | -0.61% | -7.93% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CLLS section they belong to.
Where else CLLS is measured.
CLLS earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Fate Therapeutics, Inc. (FATE) | 287 | -0.76% | 39% |
| RenovaCare, Inc. (RCAR) | 286 | 0.00% | 41% |
| Prestige Consumer Healthcare Inc. (PBH) | 285 | -0.11% | 45% |
| Xencor, Inc. (XNCR) | 285 | +0.09% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Cellectis S.A. - American Depositary Shares's median reaction calculated?
Every labeled CLLS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 285 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 37% of CLLS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CLLS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.